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Abstract
Background: Merkel cell carcinoma (MCC) is a rare but very aggressive human malignancy of elderly or
immunosuppressed patients. Clonal integration of a new human polyomavirus, the Merkel cell polyomavirus
(MCPyV), has been reported in MCC patients. The main objective of the study was the detection of MCPyV and
viral expression in clinical samples of Italian patients who were diagnosed MCC.
Findings: DNA and RNA were extracted from nine MCCs to detect the presence of MCPyV. Viral large T gene (LT1
and LT3), and viral capsid gene (VP1) were detected by polymerase chain reaction (PCR) based methods, and the
amplified PCR products were subjected to direct sequencing. The presence of viral T antigen and/or viral capsid
DNA sequences was demonstrated in eight of the nine MCC lesions, whereas RNA transcripts were detected in
three MCCs.
Conclusions: These findings indicate a potential role of MCPyV in the pathogenesis of at least a subset of MCCs.
Findings
Merkel cell carcinoma (MCC) is a rare but aggressive
human skin cancer that often appears in the older white
population. Sun exposure and immunosuppression are
likely to play a significant pathogenetic role [1,2]. Man-
agement of MCC is controversial, most of patients are
treated by surgical excision with sentinel lymph node
biopsy, followed by irradiation [3]. Conventional adju-
vant chemotherapy lacks evidence of survival benefit
and may be associated with poorer outcomes [4]. Using
digital transcriptome subtraction Feng et al. [5] reported
PCR detection of Merkel cell polyomavirus (MCPyV) in
most MCC specimens, and clonal integration of the
viral genome was identified, suggesting a role for the
virus in the pathogenesis of this skin cancer. The
M C P y Vi sas m a l lp o l y o m a v i r u sw i t hac i r c u l a rD N A
encoding a T antigen oncoprotein locus [5]. The detec-
tion frequency of MCPyV DNA in MCC seems not to
correlate with age, sex, histological subtype of carci-
noma, or the time period during which the cancer was
detected. In addition it is unclear whether integration of
MCPyV DNA into the host genome is associated with
some subtype of MCC. Nevertheless this infection could
be considered a determinant clinical factor of this rare
tumour [6].
The presence of MCPyV in MCC was already
reported by several research groups [7-9] but data
from Italian patients are lacking. The goal of this study
was the detection of the presence and expression of
MCPyV in a group of Italian MCC patients referring
to our Institution for treatment. The study included
formalin-fixed and paraffin-embedded (FFPE) resection
specimens of 9 MCC from patients treated in our
Institution. The mean age was 73 years, 6 males and 3
females. All tissue samples were collected for diagnos-
tic purposes and an informed consent at the proce-
dures, approved by the local Ethical Committee (Prot.
n. CE/312/05), was obtained from all patients. Sections
of 10 μm were obtained from FFPE tissue specimens
of the patients. The sections were extracted with
xylene to remove the paraffin, followed by two washes
with absolute ethanol to remove the xylene. DNA and
RNA were extracted by QIAamp DNA Mini kit and
RNeasy Plus Mini kit (QIAGEN, Milan, Italy), respec-
tively, according to the manufacturer’s instructions.
The presence of amplifiable DNA and RNA was con-
firmed by the amplification of human b-globin gene
[10] and of human b-Actin gene, respectively. Primers
* Correspondence: venuti@ifo.it
1Laboratory of Virology, Regina Elena Cancer Institute Via delle Messi d’Oro
156 00158 Rome, Italy
Full list of author information is available at the end of the article
Paolini et al. Virology Journal 2011, 8:103
http://www.virologyj.com/content/8/1/103
© 2011 Paolini et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.for b-Actin were Act-up (5’-ACCACACCTTCTACA
ATGAGCTGCGTG-3’)a n dA c t - d o w n( 5 ’-CACAGC
TTCTCCTTAATGTCACGCACG-3’). DNA, RNA and
PCR mixtures were prepared and kept in separate
rooms. For MCPyV DNA detection, the LT1, LT3,
V P 1a n dM 1 / 2 ,L T 5 ,V P 1 . 3 ,P 1 ,P 3 ,P 6 ,P 9 ,P 1 2L T 2
primer sets were utilised [5]. In addition, the LT1 and
M1/2 primer sets were used for nested PCR. All PCR
mixtures consisted of 500 nM of each primer, 200 μM
of each dNTP (Roche, Milan, Italy), 1 unit of thermo-
stable Platinum Taq Polymerase, 1x reaction buffer
(both from Invitrogen, Milan, Italy) and 1.5 mM
MgCl2. Total RNA was pre-treated with DNase I
(Deoxyribonuclease I, Amplification grade, Invitrogen,
Milan, Italy) and tested by RT-PCR utilizing the “One
step commercial kit” (Invitrogen, Milan, Italy) accord-
ing to the manufacturer’s instructions utilising LT1
and M1/2 primer sets for nested PCR. All amplifica-
tion reactions were performed in a i-Cycler (Bio-Rad
Laboratories, Milan, Italy). Aliquots of 15 μlf r o mt h e
PCR and RT-PCR products were submitted to electro-
phoresis in 2% ethidium bromide stained gel and were
visualised under UV light. Sterile water without DNA
or RNA template was used as PCR-negative controls.
All the purified PCR products were subjected to direct
sequencing in an automated apparatus (Biogen, Rome,
Italy). DNA sequences were compared with the refer-
ence sequences of the National Center for Biotechnol-
ogy Information (NCBI) Entrez Nucleotide database,
using the NCBI Blast program. In order to ascertain
the presence of episomal MCPyV MCC samples were
analysed by the multiply primed rolling-circle amplifi-
cation (RCA) method. This method utilizes the Ф29
DNA polymerase with random hexamer primers to
amplify the circular DNA virus genomes without the
need for prior knowledge of their DNA sequences.
Multiply primed RCA was performed with the
TempliPhi 100 amplification kit (Amersham, Bios-
ciences, Milan, Italy) according to the manufacturer’s
instructions with 450 μM extra dNTPs. Negative con-
trol samples were made with buffer without the Tem-
pliPhi enzyme. Results from the above mentioned
molecular analyses showed that eight tumours out of
the nine MCC were positive for MCPyV DNA by PCR.
Data obtained with the different primer sets are sum-
marized in Table 1 and Figure 1. One MCC was tested
positive to 9 MCPyV primer sets, two MCCs were
positive to 4 MCPyV primer sets, one MCC was posi-
tive to 3 MCPyV primer sets, four MCCs were positive
to 1 primer set and only one MCC was negative to all
MCPyV primer sets.
Amplifiable RNA was obtained for seven FFPE section
specimens of the nine MCCs. RT-PCR with LT1 and
M1/2 as nested primer sets revealed the presence of
MCPyV RNA in 3 samples (Table 1, Figure 2). The
sequences of the amplified products in all samples were
exactly matching those of MCPyV type 339 [GenBank:
EU375804.1]. In two out of nine MCPyV-positive MCCs,
episomal viral DNA was detected by RCA (Table 1).
Taken together our data demonstrate that MCPyV is
associated with MCC also in Italian patients, confirming
the results of other studies [5,7,9,11,12] in different
countries and stressing the possible role of MCPyV as
an etiologic agent in the carcinogenesis of MCC. In
addition, the presence of viral mRNAs in about 40% of
tumours (3 out of 7 samples with amplifiable RNA)
further supports the hypothesis that MCPyV plays a role
in the molecular pathogenesis of MCC [5-12]. Data
from RCA analyses lead to speculate that MCPyV is
rarely detected as episome in these tumours suggesting,
although not proving, that the virus could be integrated
and this integration may precede the clonal expansion
of tumour cells [5]. Finally confirmation of MCPyV as a
contributing factor to the pathogenesis of MCC might
Table 1 DNA, RNA, and RCA analysis for MCPyV detection
ID Gender DNA RNA RCA
b-globin LT1 VP1 LT3 M1/2 LT5 VP 1.3 P1 P3 P6 P9 P 12 LT2 LT1 Nested M1/2 b-actin LT1 Nested M1/2
1 M + + + + + - + + - + + - - +++ -
2 F + + - + - - - +--- - - + + + -
3 M + - - - - - - ---- - - + - - +
4M + -- +-- -+ - - + -- - + - -
5 M + - - - - - - ---- - - + + - -
6 F + - - - - - - ---- - - - + - +
7M + - + +-- -+ - - + -- - + + -
8 F + - - - - - - ---- - - + + - -
9 M + - - - - - - ---- - - + - - -
ID identification number of MCC patients; RCA, rolling circle amplification; LT1, LT3, M1/2, LT5, LT2 viral large T genes; VP1, VP1.3 viral caspid genes; P1, P3, P6,
P9, P12 gene-specific primers for MCPyV detection by Feng et al. [5].
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Figure 1 Amplification of LT1 (a), LT3 (b) and VP1 (c) viral
genes. PCR was performed with MCPyV specific primers; the
numbers indicate the patients as in Table 1. M8, molecular weight
marker (Roche, Milan, Italy); CTR (-), sterile water as negative control.
Figure 2 RT-PCR of total RNA from MCC samples. RT-PCR (a) was
performed with gene-specific primers for LT1; nested PCR (b) was
carried out with gene-specific primers (M1/2) within the LT1
amplicon. The numbers indicate the patients as in Table 1. M8,
molecular weight marker (Roche, Milan, Italy); CTR (-), sterile water as
negative control.
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